EAM Investors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

EAM Investors’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-34,729	Closed	-$1.08M	–	407
2014 Q3	$1.08M	Buy	+34,729	New	+$941K	0.22%	244

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

EAM Investors's SGNT Position: Q4 2014 in Review

EAM Investors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2014, closing a stake of 34,729 shares — an estimated $1.08M sold.

EAM Investors first reported a position in SGNT in Q3 2014 and held it in 1 quarter. The position peaked at $1.08M in Q3 2014. 131 funds tracked by Wall St. Rank hold SGNT as of Q4 2014.

EAM Investors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
EAM Investors sold 34,729 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2014, an estimated $1.08M.
EAM Investors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2014 and held it in 1 quarter.
EAM Investors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $1.08M in Q3 2014.
131 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2014.

Based on EAM Investors's 13F filing for Q4 2014, filed 9 Feb 2015.